Suppr超能文献

肝动脉联合切除与重建在肝门部胆管癌手术治疗中的临床应用

[Clinical application of combined hepatic artery resection and reconstruction in surgical treatment for hilar cholangiocarcinoma].

作者信息

Dai H S, Bie P, Wang S G, He Y, Li D J, Tian F, Zhao X, Chen Z Y

机构信息

Department of Hepatobiliary Surgery, the First Hospital Affiliated to Army Medical University(Southwest Hospital), Institute of Department of Hepatobiliary Surgery Research, Chongqing 400038, China.

出版信息

Zhonghua Wai Ke Za Zhi. 2018 Jan 1;56(1):41-46. doi: 10.3760/cma.j.issn.0529-5815.2018.01.010.

Abstract

To clarify whether the surgical treatment for hilar cholangiocarcinoma combined with artery reconstruction is optimistic to the patients with hilar cholangiocarcinoma with hepatic artery invasion. There were 384 patients who received treatment in the First Affiliated Hospital to Army Medical University from January 2008 to January 2016 analyzed retrospectively. There were 27 patients underwent palliative operation, 245 patients underwent radical operation, radical resection account for 63.8%. Patients were divided into four groups according to different operation method: routine radical resection group(=174), portal vein reconstruction group (=47), hepatic artery reconstruction group (=24), palliative group(=27). General information of patients who underwent radical operation treatment was analyzed by chi-square test and analysis of variance. The period of operation time, blood loss, the length of hospital stay and hospitalization expenses of the radical operation patients were analyzed by one-way ANOVA. Comparison among groups was analyzed by LSD- test. The follow-up ended up in June first, 2016. Each of patients followed for 6 to 60 months, the median follow-up period was 24 months. 1-, 3-, and 5-year survival rates were 81.3%, 44.9% and 13.5% of routine radical operation group, and were 83.0%, 44.7% and 15.1% of portal vein reconstruction group, and were 70.8%, 27.7% and 6.9% of hepatic artery reconstruction group, respectively. And 1-, 3-, and 5-year survival rates of hepatic artery reconstruction group was lower than routine radical group and portal vein reconstruction group significantly (<0.05). However, the rate of postoperative complications of the hepatic artery reconstruction group and the routine radical operation group and the portal vein reconstruction group were 62.5%(15/24), 55.3%(96/174) and 51.5%(24/47), respectively. There was no significant difference among them (>0.05). The data shows that the ratio of lymphatic metastasis in hepatic artery reconstruction group (70.8%) is much higher than them in routine radical operation group (20.1%) and portal vein reconstruction group (19.1%) significantly (<0.05). The presented data also indicate that hepatic artery resection prolongs survival time comparing with patients undergoing palliative therapy for hilar cholangiocarcinoma. Cox regression analysis indicate that hepatic artery resection and reconstruction is a protective factor compare with palliative therapy (=0.38, 95% 0.22-0.67). The significant reason for shorter survival time is a positive correlation between hepatic artery invasion and lymph node metastasis. Hepatic artery resection and reconstruction has beneficial impact on oncologic long-term outcome in patients with advanced stage hilar cholangiocarcinoma.

摘要

为阐明肝门部胆管癌手术治疗联合动脉重建对合并肝动脉侵犯的肝门部胆管癌患者的疗效是否乐观。回顾性分析2008年1月至2016年1月在陆军军医大学第一附属医院接受治疗的384例患者。其中27例行姑息性手术,245例行根治性手术,根治性切除率为63.8%。根据不同手术方式将患者分为四组:常规根治性切除组(=174)、门静脉重建组(=47)、肝动脉重建组(=24)、姑息组(=27)。采用卡方检验和方差分析对行根治性手术治疗患者的一般资料进行分析。对根治性手术患者的手术时间、出血量、住院时间和住院费用进行单因素方差分析。组间比较采用LSD检验。随访截至2016年6月1日。每位患者随访6至60个月,中位随访时间为24个月。常规根治性手术组1年、3年和5年生存率分别为81.3%、44.9%和13.5%,门静脉重建组分别为83.0%、44.7%和15.1%,肝动脉重建组分别为70.8%、27.7%和6.9%。肝动脉重建组1年、3年和5年生存率均显著低于常规根治组和门静脉重建组(<0.05)。然而,肝动脉重建组、常规根治手术组和门静脉重建组的术后并发症发生率分别为62.5%(15/24)、55.3%(96/174)和51.5%(24/47)。三组之间差异无统计学意义(>0.05)。数据显示,肝动脉重建组的淋巴结转移率(70.8%)显著高于常规根治手术组(20.1%)和门静脉重建组(19.1%)(<0.05)。所呈现的数据还表明,与接受肝门部胆管癌姑息治疗的患者相比,肝动脉切除可延长生存时间。Cox回归分析表明,与姑息治疗相比,肝动脉切除和重建是一个保护因素(=0.38,95% 0.22 - 0.67)。生存时间较短的重要原因是肝动脉侵犯与淋巴结转移呈正相关。肝动脉切除和重建对晚期肝门部胆管癌患者的肿瘤长期预后有有益影响。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验